Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

MLA

Pozo-Rosich, Patricia, et al. “Is Erenumab an Efficient Alternative for the Prevention of Episodic and Chronic Migraine in Spain? Results of a Cost-Effectiveness Analysis.” Journal of Headache & Pain, vol. 25, no. 1, Mar. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s10194-024-01747-w.

APA

Pozo-Rosich, P., Poveda, J. L., Crespo, C., Martínez, M., Rodríguez, J. M., & Irimia, P. (2024). Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis. Journal of Headache & Pain, 25(1), 1–11. https://doi.org/10.1186/s10194-024-01747-w

Chicago

Pozo-Rosich, Patricia, José Luis Poveda, Carlos Crespo, María Martínez, José Manuel Rodríguez, and Pablo Irimia. 2024. “Is Erenumab an Efficient Alternative for the Prevention of Episodic and Chronic Migraine in Spain? Results of a Cost-Effectiveness Analysis.” Journal of Headache & Pain 25 (1): 1–11. doi:10.1186/s10194-024-01747-w.